Verici Dx plc

("Verici Dx" or the "Company") 

ISO 27001 Information Security Certification Achieved

Verici Dx, a developer of advanced clinical diagnostics for organ transplant, announces that it has attained the ISO 27001 certification for its Information Security Management System ("ISMS").

ISO 27001 is an international standard specifying requirements for an ISMS, and conformity with the standard means that Verici Dx's system meets world-wide best practice with regards to managing risks related to the security of data owned or handled by the Company.

This certification underlines Verici Dx's commitment to implementing comprehensive security measures, ensuring the protection of sensitive data and information, and reinforces the Company's position as a trusted partner in industry and within patient care. With this certification, Verici Dx is well-equipped to continue delivering innovative diagnostic solutions while ensuring the highest level of protection for all sensitive information.

Dave Schultenover, VP Quality and Regulatory Affairs at Verici Dx, said: "We are pleased to have achieved the ISO 27001 certification, which underscores our unwavering commitment to maintaining the utmost security and confidentiality of data within our operations."

Patti Connolly, Chief Operating Officer at Verici Dx, added: "Achieving this international standard is testament to the quality of the Verici Dx team, and the robustness of our systems and processes that maintain the highest level of data protection for patients, clients, partners, and stakeholders."

Enquiries:

About Verici Dx plc www.vericidx.com

Verici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes.  The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage.  The Company also has a mission to accelerate the pace of innovation by research using the fully characterised data from the underlying technology, including through collaboration with medical device, biopharmaceutical and data science partners.

The foundational research was driven by a deep understanding of cell-mediated immunity and is enabled by access to expertly curated collaborative studies in highly informative cohorts in kidney transplant.